28.11.2007 22:02:00
|
AmerisourceBergen Files Annual Report on Form 10-K
AmerisourceBergen Corporation (NYSE:ABC) today filed its Annual Report
on Form 10-K for the fiscal year ended September 30, 2007 with the
Securities and Exchange Commission.
AmerisourceBergen makes available, free of charge via its website, all
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K and other information filed with or furnished to the
SEC, including amendments to such reports. This information is available
under the investors section at www.amerisourcebergen.com
as soon as reasonably practicable after it is electronically filed with
the SEC. In addition, the SEC maintains a website at www.sec.gov
that contains AmerisourceBergen information filed electronically with
them.
Alternatively, stockholders may receive a hard copy of the Annual Report
on Form 10-K, free of charge upon request. A written request should be
sent to Stockholder Relations, AmerisourceBergen Corporation, P.O. Box
959, Valley Forge, PA 19482.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both pharmaceutical manufacturers and healthcare providers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from
pharmacy automation and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With more than $66 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs more than 11,500 people. AmerisourceBergen is ranked #29 on the
Fortune 500 list. For more information, go to www.amerisourcebergen.com.
Forward-Looking Statements
This news release may contain certain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These statements are
based on management’s current expectations and
are subject to uncertainty and changes in circumstances. Actual results
may vary materially from the expectations contained in the
forward-looking statements. The following factors, among others, could
cause actual results to differ materially from those described in any
forward-looking statements: competitive pressures; the loss of one or
more key customer or supplier relationships; customer defaults or
insolvencies; changes in customer mix; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract
or other disputes with customers (including departments and agencies of
the U.S. Government) or suppliers; regulatory changes (including
increased government regulation of the pharmaceutical supply channel);
government enforcement initiatives (including (i) the imposition of
increased obligations upon pharmaceutical distributors to detect and
prevent suspicious orders of controlled substances (ii) the commencement
of further administrative actions by the U. S. Drug Enforcement
Administration seeking to suspend or revoke the license of any of the
Company’s distribution facilities to
distribute controlled substances, or (iii) the commencement of any
enforcement actions by any U.S. Attorney alleging violation of laws and
regulations regarding diversion of controlled substances and suspicious
order monitoring); changes in U.S. government policies (including
reimbursement changes arising from federal legislation, including the
Medicare Modernization Act and the Deficit Reduction Act of 2005);
changes in regulatory or clinical medical guidelines and/or
reimbursement practices for the pharmaceuticals we distribute, including
erythropoiesis-stimulating agents (ESAs) used to treat anemia patients;
price inflation in branded pharmaceuticals and price deflation in
generics; the inability of the Company to successfully complete any
transaction that the Company may wish to pursue from time to time;
fluctuations in market interest rates; operational or control issues
arising from the Company’s outsourcing of
information technology activities; success of integration, restructuring
or systems initiatives; fluctuations in the U.S. Dollar - Canadian
dollar exchange rate and other foreign exchange rates; economic,
business, competitive and/or regulatory developments in Canada, the
United Kingdom and elsewhere outside of the United States; acquisition
of businesses that do not perform as we expect or that are difficult for
us to integrate or control; any operating problems and/or cost overruns
that may be associated with the implementation of an enterprise resource
planning system; changes in tax legislation or adverse resolution of
challenges to our tax positions; and other economic, business,
competitive, legal, tax, regulatory and/or operational factors affecting
the business of the Company generally. Certain additional factors that
management believes could cause actual outcomes and results to differ
materially from those described in forward-looking statements are set
forth (i) in Item 1A (Risk Factors) in the Company’s
Annual Report on Form 10-K for the fiscal year ended September 30, 2007
and elsewhere in that report and (ii) in other reports filed by the
Company pursuant to the Securities Exchange Act of 1934.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu AmerisourceBergen Corp.mehr Nachrichten
Analysen zu AmerisourceBergen Corp.mehr Analysen
Aktien in diesem Artikel
AmerisourceBergen Corp. | 237,35 | 0,23% |
Indizes in diesem Artikel
S&P 500 | 6 047,15 | 0,24% |